Pages that link to "Q43012987"

The following pages link to Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma (Q43012987):

Displaying 22 items.

• Deficient spindle assembly checkpoint in multiple myeloma (Q21560908) (← links)
• Recent advances in the development of Aurora kinases inhibitors in hematological malignancies (Q26775723) (← links)
• Aurora kinase A in gastrointestinal cancers: time to target (Q26864277) (← links)
• Aurora kinases: novel therapy targets in cancers (Q33618929) (← links)
• Update on aurora kinase inhibitors in gynecologic malignancies (Q34576017) (← links)
• Update on aurora kinase targeted therapeutics in oncology (Q34941504) (← links)
• Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. (Q36511204) (← links)
• The potential role of Aurora kinase inhibitors in haematological malignancies (Q37167047) (← links)
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors (Q37401839) (← links)
• Cell cycle proteins as promising targets in cancer therapy (Q37693690) (← links)
• Kinase inhibitors as potential agents in the treatment of multiple myeloma (Q37697253) (← links)
• The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation (Q37709004) (← links)
• From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma (Q37880074) (← links)
• Aurora kinase inhibitors: progress towards the clinic (Q37986455) (← links)
• ENMD-2076 for hematological malignancies (Q37991379) (← links)
• Multi-kinase inhibitors, AURKs and cancer (Q38796360) (← links)
• Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy (Q38894287) (← links)
• The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro. (Q39140093) (← links)
• Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells (Q39265679) (← links)
• The therapeutic potential of cell cycle targeting in multiple myeloma (Q47203904) (← links)
• Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma (Q57818334) (← links)
• Drug Targeting of Genomic Instability in Multiple Myeloma (Q94561677) (← links)